Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
West Nile virus | 22 | 2021 | 65 | 7.050 |
Why?
|
West Nile Fever | 18 | 2021 | 56 | 5.050 |
Why?
|
Viral Nonstructural Proteins | 7 | 2021 | 45 | 2.660 |
Why?
|
Antibodies, Viral | 18 | 2023 | 262 | 2.650 |
Why?
|
JC Virus | 8 | 2010 | 24 | 2.170 |
Why?
|
Momordica charantia | 6 | 2019 | 17 | 2.100 |
Why?
|
Blood-Brain Barrier | 7 | 2016 | 162 | 1.640 |
Why?
|
Immunoassay | 6 | 2020 | 61 | 1.590 |
Why?
|
Cytokines | 10 | 2023 | 602 | 1.370 |
Why?
|
Brain | 12 | 2016 | 1346 | 1.360 |
Why?
|
Polymerase Chain Reaction | 14 | 2019 | 448 | 1.330 |
Why?
|
Virus Replication | 13 | 2021 | 278 | 1.290 |
Why?
|
Dengue Virus | 6 | 2020 | 85 | 1.280 |
Why?
|
Communicable Diseases, Emerging | 2 | 2024 | 12 | 1.110 |
Why?
|
Humans | 76 | 2024 | 37093 | 1.000 |
Why?
|
Genome, Viral | 4 | 2021 | 109 | 1.000 |
Why?
|
Polyomavirus Infections | 3 | 2010 | 21 | 0.990 |
Why?
|
Animals | 44 | 2024 | 15081 | 0.990 |
Why?
|
Zoonoses | 1 | 2024 | 17 | 0.970 |
Why?
|
Disease Models, Animal | 9 | 2017 | 1371 | 0.930 |
Why?
|
Tight Junctions | 4 | 2016 | 24 | 0.920 |
Why?
|
Microcephaly | 3 | 2020 | 19 | 0.890 |
Why?
|
Mice, Inbred C57BL | 13 | 2019 | 1609 | 0.880 |
Why?
|
Endothelial Cells | 4 | 2011 | 308 | 0.880 |
Why?
|
Monocytes | 3 | 2023 | 257 | 0.870 |
Why?
|
Diagnostic Tests, Routine | 3 | 2019 | 47 | 0.840 |
Why?
|
Cell Adhesion Molecules | 3 | 2014 | 75 | 0.830 |
Why?
|
Cross Reactions | 2 | 2020 | 83 | 0.820 |
Why?
|
Malaria, Falciparum | 2 | 2019 | 90 | 0.750 |
Why?
|
Adipose Tissue | 3 | 2019 | 177 | 0.740 |
Why?
|
Microscopy | 3 | 2019 | 32 | 0.740 |
Why?
|
Plasmodium falciparum | 2 | 2019 | 135 | 0.740 |
Why?
|
Sequence Analysis, RNA | 4 | 2024 | 106 | 0.730 |
Why?
|
Mutation | 4 | 2021 | 1095 | 0.730 |
Why?
|
Encephalitis Virus, Japanese | 1 | 2020 | 3 | 0.720 |
Why?
|
Flavivirus | 1 | 2020 | 15 | 0.710 |
Why?
|
Dengue | 4 | 2019 | 94 | 0.690 |
Why?
|
Immunoglobulin M | 3 | 2016 | 82 | 0.690 |
Why?
|
DNA, Viral | 12 | 2010 | 304 | 0.670 |
Why?
|
Antibodies, Neutralizing | 5 | 2023 | 109 | 0.670 |
Why?
|
Blood | 1 | 2019 | 37 | 0.670 |
Why?
|
Hawaii | 7 | 2024 | 1929 | 0.650 |
Why?
|
Phylogeny | 13 | 2022 | 644 | 0.650 |
Why?
|
Coronavirus Infections | 1 | 2020 | 68 | 0.650 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 76 | 0.640 |
Why?
|
Microspheres | 3 | 2019 | 49 | 0.640 |
Why?
|
Plant Extracts | 3 | 2011 | 286 | 0.640 |
Why?
|
Vero Cells | 6 | 2021 | 93 | 0.640 |
Why?
|
Beverages | 2 | 2011 | 68 | 0.630 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 26 | 0.630 |
Why?
|
Receptor, Serotonin, 5-HT2A | 2 | 2008 | 16 | 0.620 |
Why?
|
B-Lymphocytes | 2 | 2010 | 185 | 0.610 |
Why?
|
Lipid Metabolism | 2 | 2010 | 119 | 0.600 |
Why?
|
Cell Line | 12 | 2016 | 1354 | 0.600 |
Why?
|
Mice | 19 | 2023 | 5913 | 0.600 |
Why?
|
Neutralization Tests | 5 | 2021 | 53 | 0.600 |
Why?
|
Gene Expression Profiling | 5 | 2019 | 626 | 0.590 |
Why?
|
HIV-1 | 10 | 2021 | 706 | 0.590 |
Why?
|
Liver | 3 | 2011 | 479 | 0.590 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2014 | 643 | 0.580 |
Why?
|
Membrane Proteins | 4 | 2014 | 517 | 0.560 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 8 | 2016 | 448 | 0.550 |
Why?
|
RNA, Messenger | 8 | 2019 | 1207 | 0.540 |
Why?
|
Gene Expression Regulation | 7 | 2019 | 1015 | 0.540 |
Why?
|
Viral Envelope Proteins | 5 | 2022 | 82 | 0.500 |
Why?
|
Astrocytes | 3 | 2016 | 255 | 0.500 |
Why?
|
Mothers | 1 | 2016 | 181 | 0.490 |
Why?
|
Forkhead Transcription Factors | 2 | 2011 | 76 | 0.480 |
Why?
|
Sulfonamides | 2 | 2010 | 80 | 0.470 |
Why?
|
Leukocytes | 1 | 2014 | 72 | 0.460 |
Why?
|
Neurons | 5 | 2019 | 1175 | 0.460 |
Why?
|
Computational Biology | 1 | 2016 | 293 | 0.450 |
Why?
|
Protein Processing, Post-Translational | 2 | 2011 | 173 | 0.450 |
Why?
|
Sensitivity and Specificity | 6 | 2019 | 562 | 0.450 |
Why?
|
Dietary Fats | 2 | 2011 | 119 | 0.440 |
Why?
|
Endoplasmic Reticulum | 1 | 2014 | 105 | 0.440 |
Why?
|
Transcription Factors | 3 | 2010 | 681 | 0.440 |
Why?
|
Neuroglia | 3 | 2008 | 124 | 0.440 |
Why?
|
DNA Virus Infections | 3 | 2002 | 16 | 0.440 |
Why?
|
MicroRNAs | 2 | 2019 | 426 | 0.430 |
Why?
|
Interferon-alpha | 3 | 2013 | 43 | 0.430 |
Why?
|
RNA, Viral | 6 | 2010 | 301 | 0.430 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2010 | 215 | 0.430 |
Why?
|
Immunity | 1 | 2012 | 53 | 0.420 |
Why?
|
Gluconeogenesis | 1 | 2011 | 10 | 0.410 |
Why?
|
Morinda | 1 | 2011 | 9 | 0.400 |
Why?
|
Base Sequence | 11 | 2007 | 997 | 0.400 |
Why?
|
Glycolysis | 1 | 2011 | 68 | 0.390 |
Why?
|
Matrix Metalloproteinases | 2 | 2017 | 48 | 0.390 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2010 | 25 | 0.380 |
Why?
|
Nitrobenzenes | 1 | 2010 | 19 | 0.380 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 2 | 2007 | 7 | 0.380 |
Why?
|
Encephalitis | 1 | 2011 | 42 | 0.380 |
Why?
|
Dinoprostone | 1 | 2010 | 63 | 0.370 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 2 | 2017 | 24 | 0.370 |
Why?
|
Cell Death | 2 | 2010 | 267 | 0.370 |
Why?
|
Adipogenesis | 1 | 2010 | 12 | 0.370 |
Why?
|
Plant Preparations | 1 | 2010 | 27 | 0.360 |
Why?
|
Adipocytes | 1 | 2010 | 58 | 0.350 |
Why?
|
DNA Primers | 6 | 2013 | 286 | 0.350 |
Why?
|
Neurodegenerative Diseases | 1 | 2011 | 131 | 0.350 |
Why?
|
Inflammation Mediators | 1 | 2010 | 123 | 0.340 |
Why?
|
Risperidone | 1 | 2008 | 5 | 0.330 |
Why?
|
Viral Load | 3 | 2017 | 312 | 0.330 |
Why?
|
Hepatitis, Viral, Human | 2 | 1999 | 12 | 0.330 |
Why?
|
Apolipoproteins B | 2 | 2006 | 18 | 0.320 |
Why?
|
Apolipoprotein B-100 | 1 | 2008 | 7 | 0.320 |
Why?
|
Immunoglobulin G | 4 | 2021 | 237 | 0.310 |
Why?
|
Receptor, Insulin | 1 | 2008 | 25 | 0.310 |
Why?
|
Matrix Metalloproteinase 9 | 2 | 2012 | 90 | 0.310 |
Why?
|
Oxidative Stress | 2 | 2011 | 938 | 0.310 |
Why?
|
Inflammation | 2 | 2023 | 618 | 0.310 |
Why?
|
Interferon-beta | 1 | 2007 | 7 | 0.300 |
Why?
|
Female | 23 | 2020 | 20969 | 0.300 |
Why?
|
Male | 25 | 2023 | 20025 | 0.300 |
Why?
|
Sarcoma | 1 | 2007 | 10 | 0.300 |
Why?
|
Tumor Virus Infections | 1 | 2007 | 26 | 0.300 |
Why?
|
Evolution, Molecular | 3 | 2021 | 268 | 0.300 |
Why?
|
Carrier Proteins | 2 | 2010 | 305 | 0.300 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2011 | 623 | 0.290 |
Why?
|
Lymphoma | 1 | 2007 | 38 | 0.290 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2020 | 103 | 0.290 |
Why?
|
Capsid Proteins | 1 | 2007 | 67 | 0.290 |
Why?
|
HIV Protease Inhibitors | 1 | 2006 | 23 | 0.280 |
Why?
|
Obesity | 2 | 2011 | 1067 | 0.280 |
Why?
|
Hemagglutination Tests | 1 | 2006 | 3 | 0.270 |
Why?
|
Torque teno virus | 2 | 2002 | 10 | 0.270 |
Why?
|
Selenium | 1 | 2008 | 148 | 0.270 |
Why?
|
Random Allocation | 3 | 2011 | 139 | 0.270 |
Why?
|
Child | 8 | 2019 | 3131 | 0.270 |
Why?
|
Interferons | 1 | 2005 | 34 | 0.270 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 2 | 2005 | 25 | 0.270 |
Why?
|
Cucurbitaceae | 1 | 2005 | 5 | 0.260 |
Why?
|
Fetus | 2 | 2020 | 105 | 0.260 |
Why?
|
Microsomes | 1 | 2005 | 52 | 0.260 |
Why?
|
Polyomavirus | 1 | 2004 | 3 | 0.250 |
Why?
|
Virology | 1 | 2004 | 7 | 0.250 |
Why?
|
Gene Expression Regulation, Viral | 3 | 2012 | 110 | 0.250 |
Why?
|
Peromyscus | 2 | 1994 | 11 | 0.240 |
Why?
|
Cameroon | 3 | 2019 | 38 | 0.240 |
Why?
|
Culicidae | 1 | 2004 | 24 | 0.240 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2004 | 221 | 0.240 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2006 | 145 | 0.240 |
Why?
|
Body Weight | 2 | 2019 | 434 | 0.230 |
Why?
|
Infant | 5 | 2020 | 1046 | 0.230 |
Why?
|
Pulmonary Fibrosis | 1 | 2024 | 31 | 0.230 |
Why?
|
Prevalence | 6 | 2020 | 1455 | 0.230 |
Why?
|
Liver Neoplasms | 1 | 2006 | 190 | 0.230 |
Why?
|
Vaccination | 2 | 2023 | 288 | 0.230 |
Why?
|
Viremia | 4 | 2017 | 42 | 0.230 |
Why?
|
Colon | 2 | 2019 | 103 | 0.230 |
Why?
|
HIV Infections | 5 | 2010 | 2303 | 0.220 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2003 | 14 | 0.220 |
Why?
|
Adult | 13 | 2020 | 11712 | 0.220 |
Why?
|
Proteins | 1 | 2005 | 369 | 0.220 |
Why?
|
Public Policy | 1 | 2022 | 32 | 0.210 |
Why?
|
Child, Preschool | 5 | 2019 | 1418 | 0.210 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 39 | 0.210 |
Why?
|
Virulence | 3 | 2014 | 223 | 0.210 |
Why?
|
Genetic Vectors | 4 | 2021 | 158 | 0.210 |
Why?
|
Epitopes | 1 | 2022 | 148 | 0.210 |
Why?
|
DNA-Binding Proteins | 2 | 2005 | 539 | 0.200 |
Why?
|
Lipodystrophy | 1 | 2001 | 8 | 0.200 |
Why?
|
Infant, Newborn | 3 | 2020 | 894 | 0.200 |
Why?
|
Molecular Sequence Data | 9 | 2007 | 1568 | 0.200 |
Why?
|
Sequence Analysis | 1 | 2021 | 26 | 0.190 |
Why?
|
Health Policy | 1 | 2022 | 165 | 0.190 |
Why?
|
Young Adult | 5 | 2019 | 4268 | 0.190 |
Why?
|
Membrane Glycoproteins | 1 | 2022 | 211 | 0.190 |
Why?
|
Genomics | 1 | 2022 | 223 | 0.190 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 290 | 0.190 |
Why?
|
Hepatitis C | 2 | 1999 | 125 | 0.190 |
Why?
|
Cell Line, Tumor | 5 | 2008 | 2231 | 0.190 |
Why?
|
Macrophages | 2 | 2019 | 439 | 0.180 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2019 | 147 | 0.180 |
Why?
|
Reproducibility of Results | 2 | 2019 | 935 | 0.180 |
Why?
|
Adolescent | 7 | 2019 | 5363 | 0.180 |
Why?
|
Blotting, Western | 4 | 2021 | 859 | 0.170 |
Why?
|
Algorithms | 1 | 2022 | 465 | 0.170 |
Why?
|
Fruit | 2 | 2011 | 173 | 0.170 |
Why?
|
Panniculitis | 1 | 2019 | 2 | 0.170 |
Why?
|
Serologic Tests | 1 | 2019 | 43 | 0.170 |
Why?
|
West Nile Virus Vaccines | 2 | 2009 | 4 | 0.170 |
Why?
|
Freeze Drying | 1 | 2019 | 27 | 0.170 |
Why?
|
Cells, Cultured | 4 | 2019 | 1518 | 0.170 |
Why?
|
Adipokines | 1 | 2019 | 24 | 0.170 |
Why?
|
Dogs | 1 | 2019 | 149 | 0.170 |
Why?
|
Leukocytes, Mononuclear | 4 | 2024 | 234 | 0.170 |
Why?
|
Flaviviridae | 1 | 1998 | 4 | 0.170 |
Why?
|
Ebolavirus | 1 | 2019 | 42 | 0.170 |
Why?
|
Phosphoproteins | 2 | 2010 | 163 | 0.160 |
Why?
|
Reactive Oxygen Species | 1 | 2001 | 461 | 0.160 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 2010 | 356 | 0.160 |
Why?
|
Genes, nef | 1 | 1998 | 5 | 0.160 |
Why?
|
Blood Donors | 1 | 1998 | 17 | 0.160 |
Why?
|
Gene Products, nef | 1 | 1998 | 19 | 0.160 |
Why?
|
Pregnancy | 3 | 2020 | 1549 | 0.150 |
Why?
|
Doxycycline | 1 | 2017 | 30 | 0.150 |
Why?
|
Mice, Transgenic | 2 | 2023 | 617 | 0.150 |
Why?
|
Shrews | 2 | 2008 | 25 | 0.150 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2019 | 190 | 0.150 |
Why?
|
Blood Banks | 1 | 2016 | 10 | 0.150 |
Why?
|
Guinea Pigs | 1 | 2017 | 145 | 0.150 |
Why?
|
Toxoplasmosis | 1 | 2016 | 2 | 0.150 |
Why?
|
Hotlines | 1 | 2017 | 14 | 0.140 |
Why?
|
Plasmids | 2 | 2016 | 246 | 0.140 |
Why?
|
Flow Cytometry | 2 | 2015 | 399 | 0.140 |
Why?
|
Genes, env | 2 | 1996 | 13 | 0.140 |
Why?
|
Substance Abuse, Intravenous | 3 | 2007 | 121 | 0.140 |
Why?
|
Rubella | 1 | 2016 | 15 | 0.140 |
Why?
|
Immunohistochemistry | 3 | 2015 | 893 | 0.140 |
Why?
|
Saliva | 1 | 2017 | 107 | 0.140 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 2721 | 0.140 |
Why?
|
Coronary Artery Disease | 1 | 2017 | 142 | 0.140 |
Why?
|
HIV Seropositivity | 1 | 1998 | 190 | 0.140 |
Why?
|
Protein Transport | 2 | 2021 | 302 | 0.140 |
Why?
|
Typhoid Fever | 1 | 2016 | 46 | 0.140 |
Why?
|
Capillary Permeability | 1 | 2016 | 30 | 0.130 |
Why?
|
Sequence Analysis, Protein | 1 | 2016 | 50 | 0.130 |
Why?
|
Malaria | 1 | 2016 | 78 | 0.130 |
Why?
|
Drug Resistance | 1 | 2016 | 99 | 0.130 |
Why?
|
Gene Regulatory Networks | 1 | 2016 | 120 | 0.130 |
Why?
|
Blotting, Southern | 2 | 2007 | 69 | 0.130 |
Why?
|
Cell Separation | 1 | 2015 | 93 | 0.130 |
Why?
|
Cloning, Molecular | 1 | 2016 | 325 | 0.130 |
Why?
|
Chemokines | 2 | 2013 | 97 | 0.130 |
Why?
|
Hantavirus Pulmonary Syndrome | 1 | 1994 | 3 | 0.130 |
Why?
|
Sequence Analysis, DNA | 4 | 2007 | 474 | 0.130 |
Why?
|
Middle Aged | 8 | 2019 | 10129 | 0.130 |
Why?
|
Professional Competence | 1 | 2014 | 40 | 0.120 |
Why?
|
Internationality | 1 | 2014 | 32 | 0.120 |
Why?
|
Viral Matrix Proteins | 1 | 2014 | 17 | 0.120 |
Why?
|
Virus Internalization | 1 | 2014 | 28 | 0.120 |
Why?
|
Receptors, Leptin | 1 | 2014 | 13 | 0.120 |
Why?
|
Antibody Specificity | 1 | 2014 | 79 | 0.120 |
Why?
|
Defective Viruses | 2 | 2021 | 11 | 0.120 |
Why?
|
Lentivirus | 2 | 2021 | 21 | 0.120 |
Why?
|
Kinetics | 2 | 2012 | 708 | 0.120 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2014 | 35 | 0.120 |
Why?
|
Immunization | 1 | 2014 | 92 | 0.120 |
Why?
|
Interleukin-1beta | 2 | 2013 | 70 | 0.120 |
Why?
|
RNA, Transfer, Lys | 1 | 2013 | 1 | 0.120 |
Why?
|
Reverse Transcription | 1 | 2013 | 18 | 0.120 |
Why?
|
Health Services Research | 1 | 2014 | 148 | 0.120 |
Why?
|
Antigens, CD | 1 | 2014 | 121 | 0.120 |
Why?
|
Sterol Regulatory Element Binding Protein 1 | 2 | 2005 | 10 | 0.120 |
Why?
|
Spleen | 1 | 2014 | 199 | 0.110 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 218 | 0.110 |
Why?
|
Neurotoxins | 1 | 1993 | 57 | 0.110 |
Why?
|
Aged, 80 and over | 1 | 2019 | 2379 | 0.110 |
Why?
|
Aged | 4 | 2019 | 6741 | 0.110 |
Why?
|
Complement System Proteins | 1 | 2012 | 21 | 0.110 |
Why?
|
Antibody Formation | 1 | 2012 | 74 | 0.110 |
Why?
|
HTLV-I Infections | 1 | 1992 | 31 | 0.110 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 1992 | 33 | 0.110 |
Why?
|
Glucose Tolerance Test | 1 | 2012 | 68 | 0.110 |
Why?
|
Curriculum | 1 | 2014 | 265 | 0.110 |
Why?
|
Glucose Intolerance | 1 | 2012 | 42 | 0.110 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1992 | 52 | 0.100 |
Why?
|
Nerve Tissue Proteins | 2 | 2014 | 360 | 0.100 |
Why?
|
Amino Acid Sequence | 5 | 2004 | 1180 | 0.100 |
Why?
|
Matrix Metalloproteinase 3 | 1 | 2012 | 14 | 0.100 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2012 | 22 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2012 | 97 | 0.100 |
Why?
|
Species Specificity | 1 | 2012 | 245 | 0.100 |
Why?
|
Immunity, Innate | 1 | 2013 | 149 | 0.100 |
Why?
|
Hot Temperature | 1 | 2012 | 128 | 0.100 |
Why?
|
Cytopathogenic Effect, Viral | 2 | 2008 | 13 | 0.100 |
Why?
|
Cytoskeletal Proteins | 1 | 2013 | 105 | 0.100 |
Why?
|
Permeability | 1 | 2011 | 67 | 0.100 |
Why?
|
Hep G2 Cells | 1 | 2011 | 51 | 0.100 |
Why?
|
Aluminum | 3 | 1997 | 36 | 0.100 |
Why?
|
Survival Analysis | 1 | 2012 | 325 | 0.100 |
Why?
|
Creutzfeldt-Jakob Syndrome | 3 | 1996 | 28 | 0.100 |
Why?
|
Sirtuin 1 | 1 | 2011 | 32 | 0.100 |
Why?
|
Microarray Analysis | 1 | 2011 | 61 | 0.100 |
Why?
|
Pakistan | 2 | 2010 | 20 | 0.100 |
Why?
|
Gene Expression | 2 | 2012 | 674 | 0.100 |
Why?
|
Catalase | 1 | 2011 | 109 | 0.090 |
Why?
|
Glutathione Peroxidase | 1 | 2011 | 111 | 0.090 |
Why?
|
Phytotherapy | 1 | 2011 | 81 | 0.090 |
Why?
|
Fluorescein-5-isothiocyanate | 1 | 2010 | 22 | 0.090 |
Why?
|
Lymphoid Tissue | 1 | 2010 | 18 | 0.090 |
Why?
|
Cell Transformation, Viral | 1 | 2010 | 29 | 0.090 |
Why?
|
Demyelinating Diseases | 1 | 2010 | 15 | 0.090 |
Why?
|
Superoxide Dismutase | 1 | 2011 | 155 | 0.090 |
Why?
|
Lipogenesis | 1 | 2010 | 18 | 0.090 |
Why?
|
Herpesvirus 4, Human | 1 | 2010 | 33 | 0.090 |
Why?
|
Cell Movement | 1 | 2014 | 571 | 0.090 |
Why?
|
RNA Interference | 1 | 2011 | 243 | 0.090 |
Why?
|
Deoxyribonucleases | 1 | 2010 | 25 | 0.090 |
Why?
|
Phenols | 1 | 2011 | 80 | 0.090 |
Why?
|
Cyclooxygenase 2 | 1 | 2010 | 104 | 0.090 |
Why?
|
Founder Effect | 1 | 2010 | 9 | 0.090 |
Why?
|
Transduction, Genetic | 2 | 2008 | 19 | 0.090 |
Why?
|
Dipeptides | 1 | 2009 | 32 | 0.090 |
Why?
|
Neuroblastoma | 1 | 2010 | 129 | 0.090 |
Why?
|
Protease Inhibitors | 1 | 2009 | 49 | 0.090 |
Why?
|
Hypoglycemic Agents | 1 | 2011 | 160 | 0.090 |
Why?
|
Drug Users | 1 | 2010 | 46 | 0.090 |
Why?
|
Microscopy, Fluorescence | 1 | 2010 | 252 | 0.090 |
Why?
|
Dietary Supplements | 1 | 2011 | 208 | 0.080 |
Why?
|
Geese | 1 | 2008 | 4 | 0.080 |
Why?
|
Bird Diseases | 1 | 2008 | 5 | 0.080 |
Why?
|
Adenoviridae | 1 | 2008 | 62 | 0.080 |
Why?
|
Sequence Alignment | 4 | 2010 | 265 | 0.080 |
Why?
|
Moloney murine leukemia virus | 1 | 2008 | 7 | 0.080 |
Why?
|
Phosphorylation | 1 | 2011 | 928 | 0.080 |
Why?
|
Hepacivirus | 2 | 1999 | 62 | 0.080 |
Why?
|
Neuroprotective Agents | 1 | 2011 | 245 | 0.080 |
Why?
|
Cell Survival | 1 | 2011 | 864 | 0.080 |
Why?
|
Apolipoprotein B-48 | 1 | 2008 | 7 | 0.080 |
Why?
|
Transfection | 2 | 2008 | 523 | 0.080 |
Why?
|
Recombination, Genetic | 1 | 2008 | 93 | 0.080 |
Why?
|
Culture Media | 1 | 2008 | 90 | 0.080 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2021 | 188 | 0.080 |
Why?
|
Sexual Behavior | 2 | 2007 | 609 | 0.080 |
Why?
|
Kidney | 1 | 2010 | 337 | 0.080 |
Why?
|
Antioxidants | 1 | 2011 | 416 | 0.080 |
Why?
|
Vietnam | 2 | 1999 | 50 | 0.080 |
Why?
|
Antigens, Viral, Tumor | 1 | 2007 | 8 | 0.080 |
Why?
|
Interferon Regulatory Factors | 1 | 2007 | 17 | 0.080 |
Why?
|
Hantavirus Infections | 1 | 2008 | 34 | 0.080 |
Why?
|
Transcription, Genetic | 1 | 2010 | 578 | 0.070 |
Why?
|
Serotonin Antagonists | 1 | 2007 | 23 | 0.070 |
Why?
|
Endothelium, Vascular | 1 | 2009 | 237 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2010 | 587 | 0.070 |
Why?
|
Communicable Disease Control | 1 | 2007 | 32 | 0.070 |
Why?
|
Apolipoprotein C-III | 1 | 2006 | 5 | 0.070 |
Why?
|
Antiviral Agents | 1 | 2008 | 157 | 0.070 |
Why?
|
Apolipoprotein A-I | 1 | 2006 | 21 | 0.070 |
Why?
|
Intestinal Mucosa | 1 | 2007 | 122 | 0.070 |
Why?
|
Insulin Resistance | 1 | 2008 | 184 | 0.070 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 409 | 0.070 |
Why?
|
Gene Dosage | 1 | 2006 | 75 | 0.070 |
Why?
|
Escherichia coli | 1 | 2008 | 453 | 0.070 |
Why?
|
Apolipoproteins E | 1 | 2006 | 129 | 0.060 |
Why?
|
Oleic Acid | 1 | 2005 | 19 | 0.060 |
Why?
|
Dendrites | 2 | 1997 | 55 | 0.060 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 2004 | 7 | 0.060 |
Why?
|
Risk-Taking | 2 | 1999 | 451 | 0.060 |
Why?
|
Electrophoresis, Agar Gel | 1 | 2004 | 28 | 0.060 |
Why?
|
Glioblastoma | 1 | 2005 | 55 | 0.060 |
Why?
|
Cytosol | 1 | 2005 | 93 | 0.060 |
Why?
|
Up-Regulation | 3 | 2019 | 513 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2005 | 306 | 0.060 |
Why?
|
Anopheles | 1 | 2004 | 17 | 0.060 |
Why?
|
Databases, Nucleic Acid | 1 | 2004 | 27 | 0.060 |
Why?
|
Aedes | 1 | 2004 | 34 | 0.060 |
Why?
|
Myeloid Cells | 1 | 2024 | 29 | 0.060 |
Why?
|
Bystander Effect | 1 | 2023 | 11 | 0.060 |
Why?
|
Half-Life | 1 | 2023 | 54 | 0.060 |
Why?
|
Pilot Projects | 2 | 2019 | 661 | 0.060 |
Why?
|
Protein Structure, Tertiary | 2 | 2014 | 408 | 0.060 |
Why?
|
Blood Cells | 1 | 2002 | 8 | 0.060 |
Why?
|
Cell Nucleus | 1 | 2005 | 366 | 0.060 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2003 | 47 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 161 | 0.050 |
Why?
|
Blood Transfusion | 1 | 2002 | 27 | 0.050 |
Why?
|
Granulocytes | 1 | 2022 | 29 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2004 | 259 | 0.050 |
Why?
|
Protein Structure, Secondary | 2 | 2012 | 183 | 0.050 |
Why?
|
Acute Disease | 1 | 2003 | 147 | 0.050 |
Why?
|
Bone Marrow Cells | 1 | 2002 | 81 | 0.050 |
Why?
|
Antigens, CD19 | 1 | 2002 | 15 | 0.050 |
Why?
|
Ammonium Chloride | 1 | 2021 | 4 | 0.050 |
Why?
|
Convalescence | 1 | 2021 | 7 | 0.050 |
Why?
|
Antigen-Antibody Reactions | 1 | 2021 | 20 | 0.050 |
Why?
|
Testis | 1 | 2023 | 187 | 0.050 |
Why?
|
Genetics, Population | 1 | 2002 | 100 | 0.050 |
Why?
|
Emigration and Immigration | 1 | 2002 | 82 | 0.050 |
Why?
|
Virus Integration | 1 | 2002 | 58 | 0.050 |
Why?
|
Point Mutation | 1 | 2021 | 93 | 0.050 |
Why?
|
Genes, Reporter | 1 | 2021 | 136 | 0.050 |
Why?
|
Disease Progression | 1 | 2024 | 601 | 0.050 |
Why?
|
Endoplasmic Reticulum, Rough | 1 | 2021 | 3 | 0.050 |
Why?
|
RNA Helicases | 1 | 2021 | 16 | 0.050 |
Why?
|
Serine Endopeptidases | 1 | 2021 | 38 | 0.050 |
Why?
|
Genes, Viral | 2 | 1998 | 63 | 0.050 |
Why?
|
Pregnancy Trimesters | 1 | 2020 | 14 | 0.050 |
Why?
|
Cytoplasm | 1 | 2021 | 143 | 0.050 |
Why?
|
Apoptosis | 1 | 2008 | 1398 | 0.050 |
Why?
|
Age of Onset | 1 | 2020 | 100 | 0.050 |
Why?
|
Recombinant Proteins | 2 | 2019 | 515 | 0.050 |
Why?
|
Phenotype | 1 | 2022 | 689 | 0.040 |
Why?
|
Incidence | 1 | 2002 | 922 | 0.040 |
Why?
|
Liberia | 1 | 2019 | 13 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2005 | 807 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2019 | 68 | 0.040 |
Why?
|
Hepatitis Viruses | 1 | 1999 | 3 | 0.040 |
Why?
|
Vaccines, Subunit | 2 | 2009 | 30 | 0.040 |
Why?
|
High-Throughput Screening Assays | 1 | 2019 | 65 | 0.040 |
Why?
|
DNA Viruses | 1 | 1999 | 14 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 1998 | 30 | 0.040 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 1998 | 11 | 0.040 |
Why?
|
Receptors, CCR5 | 1 | 1999 | 61 | 0.040 |
Why?
|
Risk Factors | 1 | 2007 | 3562 | 0.040 |
Why?
|
Sequence Deletion | 1 | 1999 | 87 | 0.040 |
Why?
|
Cohort Studies | 1 | 2022 | 1492 | 0.040 |
Why?
|
DNA, Complementary | 1 | 1998 | 191 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2017 | 9 | 0.040 |
Why?
|
Elastin | 1 | 2017 | 40 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 1999 | 191 | 0.040 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 1998 | 51 | 0.040 |
Why?
|
Mitochondria | 1 | 2001 | 487 | 0.040 |
Why?
|
China | 1 | 1998 | 196 | 0.040 |
Why?
|
Optic Nerve | 2 | 1995 | 28 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2017 | 286 | 0.040 |
Why?
|
Pacific Ocean | 1 | 2017 | 13 | 0.040 |
Why?
|
Echocardiography | 1 | 2017 | 144 | 0.040 |
Why?
|
Inclusion Bodies | 1 | 1996 | 33 | 0.040 |
Why?
|
Insecticide-Treated Bednets | 1 | 2016 | 8 | 0.040 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 1996 | 46 | 0.040 |
Why?
|
Down-Regulation | 1 | 2019 | 435 | 0.040 |
Why?
|
Sex Factors | 1 | 2020 | 898 | 0.040 |
Why?
|
Cats | 1 | 2016 | 69 | 0.040 |
Why?
|
Health Facilities | 1 | 2016 | 27 | 0.040 |
Why?
|
Point-of-Care Systems | 1 | 2016 | 27 | 0.040 |
Why?
|
Interleukin-1 | 1 | 1996 | 35 | 0.040 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 1996 | 70 | 0.040 |
Why?
|
HIV Seroprevalence | 1 | 1996 | 14 | 0.040 |
Why?
|
Brain Stem | 1 | 1996 | 50 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 268 | 0.030 |
Why?
|
Thailand | 1 | 1996 | 48 | 0.030 |
Why?
|
Temperature | 1 | 2017 | 286 | 0.030 |
Why?
|
Fever | 1 | 2016 | 57 | 0.030 |
Why?
|
Ultrasonography, Prenatal | 1 | 2016 | 33 | 0.030 |
Why?
|
Spinal Cord | 1 | 1996 | 94 | 0.030 |
Why?
|
Antimalarials | 1 | 2016 | 55 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2008 | 269 | 0.030 |
Why?
|
Occupational Diseases | 1 | 1996 | 47 | 0.030 |
Why?
|
Placenta | 1 | 2016 | 97 | 0.030 |
Why?
|
Genetic Variation | 2 | 2002 | 387 | 0.030 |
Why?
|
Research | 1 | 2017 | 163 | 0.030 |
Why?
|
Encephalitis, Viral | 1 | 1995 | 6 | 0.030 |
Why?
|
Human T-lymphotropic virus 2 | 1 | 1995 | 1 | 0.030 |
Why?
|
Indians, South American | 1 | 1995 | 8 | 0.030 |
Why?
|
Membranes | 1 | 2014 | 19 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2014 | 132 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2014 | 83 | 0.030 |
Why?
|
Protein Precursors | 1 | 2014 | 61 | 0.030 |
Why?
|
RNA, Complementary | 1 | 2013 | 9 | 0.030 |
Why?
|
Bunyaviridae Infections | 1 | 1993 | 5 | 0.030 |
Why?
|
Hemorrhagic Fever with Renal Syndrome | 1 | 1993 | 21 | 0.030 |
Why?
|
Southwestern United States | 1 | 1993 | 40 | 0.030 |
Why?
|
Nucleotides | 1 | 1993 | 36 | 0.030 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1993 | 1 | 0.030 |
Why?
|
Leukemia, Lymphoid | 1 | 1993 | 4 | 0.030 |
Why?
|
Thymidine | 1 | 1993 | 15 | 0.030 |
Why?
|
Plasticizers | 1 | 1993 | 7 | 0.030 |
Why?
|
Prospective Studies | 1 | 2017 | 1378 | 0.030 |
Why?
|
Tritium | 1 | 1993 | 51 | 0.030 |
Why?
|
Fluorouracil | 1 | 1993 | 34 | 0.030 |
Why?
|
Hippocampus | 1 | 1997 | 561 | 0.030 |
Why?
|
Aluminum Compounds | 1 | 1993 | 8 | 0.030 |
Why?
|
L-Lactate Dehydrogenase | 1 | 1993 | 62 | 0.030 |
Why?
|
Caspase 1 | 1 | 2013 | 15 | 0.030 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2013 | 11 | 0.030 |
Why?
|
Antibody Affinity | 1 | 2012 | 25 | 0.030 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2012 | 42 | 0.030 |
Why?
|
Phosphates | 1 | 1993 | 51 | 0.030 |
Why?
|
Protein Stability | 1 | 2012 | 45 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 1998 | 458 | 0.030 |
Why?
|
Amino Acids | 1 | 1993 | 145 | 0.030 |
Why?
|
Melanesia | 1 | 1992 | 22 | 0.030 |
Why?
|
Papua New Guinea | 1 | 1992 | 21 | 0.030 |
Why?
|
Base Composition | 1 | 1992 | 23 | 0.030 |
Why?
|
Templates, Genetic | 1 | 1992 | 25 | 0.030 |
Why?
|
Glioma | 1 | 1993 | 79 | 0.030 |
Why?
|
Motor Neurons | 1 | 1993 | 83 | 0.030 |
Why?
|
Cell Division | 1 | 1993 | 307 | 0.030 |
Why?
|
DNA Replication | 1 | 1993 | 152 | 0.030 |
Why?
|
DNA, Single-Stranded | 1 | 1992 | 37 | 0.030 |
Why?
|
Nerve Degeneration | 1 | 1993 | 107 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2013 | 113 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 1993 | 502 | 0.030 |
Why?
|
California | 1 | 1993 | 476 | 0.030 |
Why?
|
Taste | 1 | 2011 | 41 | 0.020 |
Why?
|
Pacific Islands | 2 | 2002 | 119 | 0.020 |
Why?
|
Vegetables | 1 | 2011 | 147 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2013 | 933 | 0.020 |
Why?
|
Transients and Migrants | 1 | 2010 | 39 | 0.020 |
Why?
|
Protein Binding | 1 | 2012 | 972 | 0.020 |
Why?
|
Vaccines, Synthetic | 1 | 2009 | 72 | 0.020 |
Why?
|
Blood Glucose | 1 | 2011 | 353 | 0.020 |
Why?
|
Macaca mulatta | 1 | 2009 | 128 | 0.020 |
Why?
|
Genetic Techniques | 1 | 2008 | 15 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2009 | 142 | 0.020 |
Why?
|
Virus Assembly | 1 | 2008 | 41 | 0.020 |
Why?
|
Population Surveillance | 1 | 2010 | 238 | 0.020 |
Why?
|
Disease Reservoirs | 1 | 2008 | 20 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2008 | 90 | 0.020 |
Why?
|
Drosophila melanogaster | 1 | 2009 | 180 | 0.020 |
Why?
|
United States | 2 | 2008 | 4223 | 0.020 |
Why?
|
Myelin Sheath | 2 | 1996 | 48 | 0.020 |
Why?
|
Rats | 1 | 1993 | 3483 | 0.020 |
Why?
|
Models, Genetic | 1 | 2006 | 172 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2006 | 208 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2006 | 208 | 0.020 |
Why?
|
Diet | 1 | 2011 | 801 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2005 | 195 | 0.020 |
Why?
|
Lung | 1 | 2008 | 446 | 0.020 |
Why?
|
Microscopy, Electron | 2 | 1996 | 209 | 0.020 |
Why?
|
Rabbits | 2 | 1996 | 283 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2009 | 1198 | 0.010 |
Why?
|
Genotype | 1 | 2002 | 730 | 0.010 |
Why?
|
Asia | 1 | 1999 | 75 | 0.010 |
Why?
|
Heterozygote | 1 | 1999 | 93 | 0.010 |
Why?
|
Gene Frequency | 1 | 1999 | 195 | 0.010 |
Why?
|
Alleles | 1 | 1999 | 321 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1996 | 150 | 0.010 |
Why?
|
Biological Transport | 1 | 1997 | 185 | 0.010 |
Why?
|
HTLV-II Infections | 1 | 1995 | 6 | 0.010 |
Why?
|
Gene Products, tax | 1 | 1995 | 4 | 0.010 |
Why?
|
Genetic Heterogeneity | 1 | 1995 | 9 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 1999 | 628 | 0.010 |
Why?
|
Colombia | 1 | 1995 | 20 | 0.010 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1995 | 31 | 0.010 |
Why?
|
Serotyping | 1 | 1995 | 36 | 0.010 |
Why?
|
Antigens, Viral | 1 | 1995 | 43 | 0.010 |
Why?
|
RNA | 1 | 1997 | 241 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 1995 | 91 | 0.010 |
Why?
|
Nucleic Acid Conformation | 1 | 1995 | 146 | 0.010 |
Why?
|
Gamma Rays | 1 | 1993 | 26 | 0.010 |
Why?
|
Mice, Inbred ICR | 1 | 1993 | 40 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1993 | 122 | 0.010 |
Why?
|
Chemistry, Pharmaceutical | 1 | 1993 | 71 | 0.010 |
Why?
|
Drug Stability | 1 | 1993 | 116 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1993 | 108 | 0.010 |
Why?
|
Liposomes | 1 | 1993 | 118 | 0.010 |
Why?
|
Drug Carriers | 1 | 1993 | 125 | 0.010 |
Why?
|
Time Factors | 1 | 1996 | 1742 | 0.010 |
Why?
|